The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
Matteo Santoni
No relevant relationships to disclose
Camillo Porta
No relevant relationships to disclose
Giuseppe Procopio
No relevant relationships to disclose
Linda Cerbone
No relevant relationships to disclose
Umberto Basso
No relevant relationships to disclose
Ugo De Giorgi
No relevant relationships to disclose
Mimma Rizzo
No relevant relationships to disclose
Cinzia Ortega
No relevant relationships to disclose
Francesco Massari
No relevant relationships to disclose
Roberto Iacovelli
No relevant relationships to disclose
Giuseppe di Lorenzo
No relevant relationships to disclose
Michele Milella
No relevant relationships to disclose
Roberto Sabbatini
No relevant relationships to disclose
Francesco Atzori
No relevant relationships to disclose
Rocco De Vivo
No relevant relationships to disclose
Rossana Berardi
No relevant relationships to disclose
Daniele Santini
No relevant relationships to disclose
Stefano Cascinu
No relevant relationships to disclose